Turning Point Therapeutics (NASDAQ:TPTX) CFO Yi Larson purchased 2,222 shares of the stock in a transaction dated Tuesday, September 10th. The shares were bought at an average price of $45.00 per share, for a total transaction of $99,990.00.
NASDAQ:TPTX traded up $0.50 during trading hours on Thursday, reaching $45.51. The company’s stock had a trading volume of 11,692 shares, compared to its average volume of 203,889. Turning Point Therapeutics has a one year low of $24.21 and a one year high of $58.56. The business has a 50-day moving average of $45.11. The company has a current ratio of 32.35, a quick ratio of 32.35 and a debt-to-equity ratio of 0.01.
Turning Point Therapeutics (NASDAQ:TPTX) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.65) by ($0.05). On average, sell-side analysts forecast that Turning Point Therapeutics will post -2.88 earnings per share for the current fiscal year.
A number of large investors have recently modified their holdings of TPTX. Tower Research Capital LLC TRC bought a new stake in Turning Point Therapeutics in the second quarter worth $25,000. JPMorgan Chase & Co. bought a new stake in Turning Point Therapeutics in the second quarter worth $71,000. Wells Fargo & Company MN bought a new stake in Turning Point Therapeutics in the second quarter worth $72,000. Cubist Systematic Strategies LLC bought a new stake in Turning Point Therapeutics in the second quarter worth $90,000. Finally, Alpine Woods Capital Investors LLC bought a new stake in Turning Point Therapeutics in the second quarter worth $204,000. Hedge funds and other institutional investors own 58.17% of the company’s stock.
About Turning Point Therapeutics
Turning Point Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.
Read More: How does a margin account work?
Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.